GCP
IPXL

GSA Capital Partners’s Impax Laboratories, Inc. IPXL Stock Holding History

GSA Capital Partners’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-20,294
Closed -$269K – 2158
2016
Q4 		$269K Sell
20,294
-4,706
-19% -$80.5K 0.02% 1401
2016
Q3 		$593K Buy
25,000
+14,204
+132% +$382K 0.03% 953
2016
Q2 		$311K Buy
+10,796
New +$352K 0.02% 1363

Other funds holding IPXL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

GSA Capital Partners's IPXL Position: Q1 2017 in Review

GSA Capital Partners sold out of Impax Laboratories, Inc. (IPXL) in Q1 2017, closing a stake of 20,294 shares — an estimated $269K sold.

GSA Capital Partners first reported a position in IPXL in Q2 2016 and held it in 3 quarters. The position peaked at $593K in Q3 2016. 178 funds tracked by Wall St. Rank hold IPXL as of Q1 2017.

  • GSA Capital Partners reported no remaining Impax Laboratories, Inc. position as of Q1 2017 after selling out during the quarter.
  • GSA Capital Partners sold 20,294 Impax Laboratories, Inc. shares in Q1 2017, an estimated $269K.
  • GSA Capital Partners first reported a position in Impax Laboratories, Inc. in Q2 2016 and held it in 3 quarters.
  • GSA Capital Partners's Impax Laboratories, Inc. position peaked at $593K in Q3 2016.
  • 178 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q1 2017.

Based on GSA Capital Partners's 13F filing for Q1 2017, filed 15 May 2017.